Bicara Therapeutics (BCAX) Change in Accured Expenses (2023 - 2026)

Bicara Therapeutics (BCAX) has 4 years of Change in Accured Expenses data on file, last reported at -$1.4 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses fell 141.29% year-over-year to -$1.4 million; the trailing twelve-month figure through Mar 2026 stood at $3.0 million (down 68.14% YoY), and the FY2025 full-year result was $7.7 million, up 15.54% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$1.4 million, down from $6.3 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $15.1 million in Q4 2023 and bottomed at -$1.8 million in Q2 2025.
• The 4-year median for Change in Accured Expenses is $1.2 million (2024), against an average of $2.8 million.
• The widest annual swing landed in 2025, when Change in Accured Expenses jumped 692.03%; it then sank 141.29% in 2026.
• A 4-year view of Change in Accured Expenses shows it stood at $15.1 million in 2023, then tumbled by 60.9% to $5.9 million in 2024, then advanced by 7.24% to $6.3 million in 2025, then plunged by 121.4% to -$1.4 million in 2026.
• The last three Change in Accured Expenses figures came in at -$1.4 million (Q1 2026), $6.3 million (Q4 2025), and -$168000.0 (Q3 2025), per Business Quant data.

Peer Comparison